<?xml version='1.0' encoding='utf-8'?>
<document id="27209586"><sentence text="A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993."><entity charOffset="121-131" id="DDI-PubMed.27209586.s1.e0" text="Cimetidine" /></sentence><sentence text="CHF 5993 is an extrafine 'triple therapy' combination of the long-acting muscarinic antagonist glycopyrronium bromide (GB), the long-acting β2-agonist formoterol fumarate (FF), and the inhaled corticosteroid beclometasone dipropionate (BDP)"><entity charOffset="95-117" id="DDI-PubMed.27209586.s2.e0" text="glycopyrronium bromide" /><entity charOffset="151-170" id="DDI-PubMed.27209586.s2.e1" text="formoterol fumarate" /><entity charOffset="172-174" id="DDI-PubMed.27209586.s2.e2" text="FF" /><entity charOffset="208-234" id="DDI-PubMed.27209586.s2.e3" text="beclometasone dipropionate" /><entity charOffset="236-239" id="DDI-PubMed.27209586.s2.e4" text="BDP" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e0" e2="DDI-PubMed.27209586.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e0" e2="DDI-PubMed.27209586.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e0" e2="DDI-PubMed.27209586.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e0" e2="DDI-PubMed.27209586.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e0" e2="DDI-PubMed.27209586.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e1" e2="DDI-PubMed.27209586.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e1" e2="DDI-PubMed.27209586.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e1" e2="DDI-PubMed.27209586.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e1" e2="DDI-PubMed.27209586.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e2" e2="DDI-PubMed.27209586.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e2" e2="DDI-PubMed.27209586.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e2" e2="DDI-PubMed.27209586.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e3" e2="DDI-PubMed.27209586.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27209586.s2.e3" e2="DDI-PubMed.27209586.s2.e4" /></sentence><sentence text=" It is in development for chronic obstructive pulmonary disease and asthma delivered via pressurised metered-dose inhaler" /><sentence text="" /><sentence text="This two-period, open-label, crossover study examined the drug-drug interaction of CHF 5993 and cimetidine"><entity charOffset="96-106" id="DDI-PubMed.27209586.s5.e0" text="cimetidine" /></sentence><sentence text=" In one period, subjects received cimetidine 800 mg twice daily for 6 days; on the fourth day they also received CHF 5993 (BDP/FF/GB 400/24/100 µg)"><entity charOffset="34-44" id="DDI-PubMed.27209586.s6.e0" text="cimetidine" /><entity charOffset="127-136" id="DDI-PubMed.27209586.s6.e1" text="FF" /><entity charOffset="123-132" id="DDI-PubMed.27209586.s6.e2" text="BDP" /><pair ddi="false" e1="DDI-PubMed.27209586.s6.e0" e2="DDI-PubMed.27209586.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27209586.s6.e0" e2="DDI-PubMed.27209586.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s6.e0" e2="DDI-PubMed.27209586.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27209586.s6.e2" e2="DDI-PubMed.27209586.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s6.e2" e2="DDI-PubMed.27209586.s6.e1" /></sentence><sentence text=" In the other, they received CHF 5993 alone" /><sentence text=" Primary objective was to compare the area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUC0-t) of GB, with and without cimetidine"><entity charOffset="165-175" id="DDI-PubMed.27209586.s8.e0" text="cimetidine" /></sentence><sentence text=" Secondary endpoints included GB AUC0-12h, maximum concentration (C max), time to C max (t max), elimination half-life (t ½) and urinary excretion" /><sentence text=" Pharmacokinetic parameters of BDP, beclometasone-17-monopropionate (B17MP; active metabolite of BDP) and formoterol were also evaluated"><entity charOffset="36-67" id="DDI-PubMed.27209586.s10.e0" text="beclometasone-17-monopropionate" /><entity charOffset="69-74" id="DDI-PubMed.27209586.s10.e1" text="B17MP" /><entity charOffset="97-100" id="DDI-PubMed.27209586.s10.e2" text="BDP" /><entity charOffset="106-116" id="DDI-PubMed.27209586.s10.e3" text="formoterol" /><entity charOffset="31-40" id="DDI-PubMed.27209586.s10.e4" text="BDP" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e4" e2="DDI-PubMed.27209586.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e4" e2="DDI-PubMed.27209586.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e4" e2="DDI-PubMed.27209586.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e4" e2="DDI-PubMed.27209586.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e4" e2="DDI-PubMed.27209586.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e0" e2="DDI-PubMed.27209586.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e0" e2="DDI-PubMed.27209586.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e0" e2="DDI-PubMed.27209586.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e0" e2="DDI-PubMed.27209586.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e1" e2="DDI-PubMed.27209586.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e1" e2="DDI-PubMed.27209586.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e1" e2="DDI-PubMed.27209586.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e2" e2="DDI-PubMed.27209586.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27209586.s10.e2" e2="DDI-PubMed.27209586.s10.e3" /></sentence><sentence text="" /><sentence text="Twenty-six subjects were randomised; 25 completed" /><sentence text=" Co-administration of CHF 5993 and cimetidine resulted in small, statistically significant increases in GB AUC0-t, AUC0-12h and C max vs CHF 5993 (ratios 1"><entity charOffset="35-45" id="DDI-PubMed.27209586.s13.e0" text="cimetidine" /></sentence><sentence text="16, 1" /><sentence text="21 and 1" /><sentence text="26, respectively); t ½, t max and urinary excretion were unaffected" /><sentence text=" There were small, statistically significant increases in formoterol AUC0-t, AUC0-24h and t ½ following co-administration of cimetidine and CHF 5993; urinary excretion was unaffected"><entity charOffset="125-135" id="DDI-PubMed.27209586.s17.e0" text="cimetidine" /></sentence><sentence text=" There were no significant differences for either BDP or B17MP"><entity charOffset="50-59" id="DDI-PubMed.27209586.s18.e0" text="BDP" /><entity charOffset="57-66" id="DDI-PubMed.27209586.s18.e1" text="B17MP" /><pair ddi="false" e1="DDI-PubMed.27209586.s18.e0" e2="DDI-PubMed.27209586.s18.e0" /><pair ddi="false" e1="DDI-PubMed.27209586.s18.e0" e2="DDI-PubMed.27209586.s18.e1" /></sentence><sentence text=" There were few adverse events (AEs), and no serious AEs" /><sentence text="" /><sentence text="Overall, this study indicates that there is no clinically relevant drug-drug interaction between CHF 5993 and cimetidine"><entity charOffset="110-120" id="DDI-PubMed.27209586.s21.e0" text="cimetidine" /></sentence><sentence text="" /></document>